Abdominal aortic aneurysm—an independent disease to atherosclerosis?

Cardiovascular Pathology

Volumn 27, Issue , 2017, Pages 71-75

  Toghill, Bradley J ^a   Saratzis, Athanasios ^a   Bown, Matthew J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Abdominal aortic aneurysm; Atherosclerosis; Cardiovascular disease; Inflammation; Multifactorial; Polygenic

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HOMOCYSTEINE;

ABDOMINAL AORTA ANEURYSM; AORTA WALL; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DNA METHYLATION; GENETIC BACKGROUND; GENETIC POLYMORPHISM; GENOME-WIDE ASSOCIATION STUDY; HEREDITY; HUMAN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; AORTIC ANEURYSM, ABDOMINAL; COMPLICATION; CORONARY ARTERY DISEASE; RISK FACTOR;

AORTIC ANEURYSM, ABDOMINAL; CORONARY ARTERY DISEASE; HUMANS; RISK FACTORS;

EID: 85011798882     PISSN: 10548807     EISSN: 18791336     Source Type: Journal    
DOI: 10.1016/j.carpath.2017.01.008     Document Type: Review

References (74)

1. [1] Sidloff, D., Stather, P., Dattani, N., Bown, M., Thompson, J., Sayers, R., et al. Aneurysm global epidemiology study: public health measures can further reduce abdominal aortic aneurysm mortality. Circulation 129 (2014), 747–753.
2. [2] Toghill, B.J., Saratzis, A., Harrison, S.C., Verissimo, A.R., Mallon, E.B., Bown, M.J., The potential role of DNA methylation in the pathogenesis of abdominal aortic aneurysm. Atherosclerosis 241 (2015), 121–129.
3. [3] Campbell, W.B., Mortality statistics for elective aortic aneurysms. Eur J Vasc Surg 5 (1991), 111–113.
4. [4] Holt, P.J., Poloniecki, J.D., Gerrard, D., Loftus, I.M., Thompson, M.M., Meta-analysis and systematic review of the relationship between volume and outcome in abdominal aortic aneurysm surgery. Br J Surg 94 (2007), 395–403.
5. [5] Diehm, N., Dick, F., Schaffner, T., Schmidli, J., Kalka, C., Di Santo, S., et al. Novel insight into the pathobiology of abdominal aortic aneurysm and potential future treatment concepts. Prog Cardiovasc Dis 50 (2007), 209–217.
6. [6] Meijer, C.A., Stijnen, T., Wasser, M.N., Hamming, J.F., van Bockel, J.H., Lindeman, J.H., Doxycycline for stabilization of abdominal aortic aneurysms: a randomized trial. Ann Intern Med 159 (2013), 815–823.
7. [7] Saratzis, A., Bown, M.J., The genetic basis for aortic aneurysmal disease. Heart 100 (2014), 916–922.
8. [8] Toghill, B.J., Saratzis, A., Liyanage, L.S., Sidloff, D., Bown, M.J., Genetics of Aortic Aneurysmal Disease. 2016, John Wiley & Sons, Ltd., eLS.
9. [9] Wahlgren, C.M., Larsson, E., Magnusson, P.K., Hultgren, R., Swedenborg, J., Genetic and environmental contributions to abdominal aortic aneurysm development in a twin population. J Vasc Surg 51 (2010), 3–7 [discussion].
10. [10] Wassef, M., Baxter, B.T., Chisholm, R.L., Dalman, R.L., Fillinger, M.F., Heinecke, J., et al. Pathogenesis of abdominal aortic aneurysms: A multidisciplinary research program supported by the National Heart, Lung, and Blood Institute. J Vasc Surg 34 (2001), 730–738.
11. [11] Pearce, W.H., Shively, V.P., Abdominal aortic aneurysm as a complex multifactorial disease: interactions of polymorphisms of inflammatory genes, features of autoimmunity, and current status of MMPs. Ann N Y Acad Sci 1085 (2006), 117–132.
12. [12] Longo, G.M., Buda, S.J., Fiotta, N., Xiong, W., Griener, T., Shapiro, S., et al. MMP-12 has a role in abdominal aortic aneurysms in mice. Surgery 137 (2005), 457–462.
13. [13] Palazzuoli, A., Gallotta, M., Guerrieri, G., Quatrini, I., Franci, B., Campagna, M.S., et al. Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: comparison with high cardiovascular risk population. Vasc Health Risk Manag 4 (2008), 877–883.
14. [14] Bradley, D.T., Hughes, A.E., Badger, S.A., Jones, G.T., Harrison, S.C., Wright, B.J., et al. A variant in LDLR is associated with abdominal aortic aneurysm. Circ Cardiovasc Genet 6 (2013), 498–504.
15. [15] Herijgers, N., Van Eck, M., Groot, P.H., Hoogerbrugge, P.M., Van Berkel, T.J., Low density lipoprotein receptor of macrophages facilitates atherosclerotic lesion formation in C57Bl/6 mice. Arterioscler Thromb Vasc Biol 20 (2000), 1961–1967.
16. [16] Cornuz, J., Sidoti Pinto, C., Tevaearai, H., Egger, M., Risk factors for asymptomatic abdominal aortic aneurysm: systematic review and meta-analysis of population-based screening studies. Eur J Pub Health 14 (2004), 343–349.
17. [17] Golledge, J., Norman, P.E., Atherosclerosis and abdominal aortic aneurysm: cause, response, or common risk factors?. Arterioscler Thromb Vasc Biol 30 (2010), 1075–1077.
18. [18] Peshkova, I.O., Schaefer, G., Koltsova, E.K., Atherosclerosis and aortic aneurysm - is inflammation a common denominator?. FEBS J 283 (2016), 1636–1652.
19. [19] Elkalioubie, A., Haulon, S., Duhamel, A., Rosa, M., Rauch, A., Staels, B., et al. Meta-Analysis of Abdominal Aortic Aneurysm in Patients With Coronary Artery Disease. Am J Cardiol 116 (2015), 1451–1456.
20. [20] Lee, A.J., Fowkes, F.G., Carson, M.N., Leng, G.C., Allan, P.L., Smoking, atherosclerosis and risk of abdominal aortic aneurysm. Eur Heart J 18 (1997), 671–676.
21. [21] Ito, S., Akutsu, K., Tamori, Y., Sakamoto, S., Yoshimuta, T., Hashimoto, H., et al. Differences in Atherosclerotic Profiles Between Patients With Thoracic and Abdominal Aortic Aneurysms. Am J Cardiol 101 (2008), 696–699.
22. [22] Johnsen, S.H., Forsdahl, S.H., Singh, K., Jacobsen, B.K., Atherosclerosis in abdominal aortic aneurysms: a causal event or a process running in parallel? The Tromso study. Arterioscler Thromb Vasc Biol 30 (2010), 1263–1268.
23. [23] De Rango, P., Farchioni, L., Fiorucci, B., Lenti, M., Diabetes and abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 47 (2014), 243–261.
24. [24] Lederle, F.A., The strange relationship between diabetes and abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 43 (2012), 254–256.
25. [25] Torsney, E., Pirianov, G., Cockerill, G.W., Diabetes as a negative risk factor for abdominal aortic aneurysm - does the disease aetiology or the treatment provide the mechanism of protection?. Curr Vasc Pharmacol 11 (2013), 293–298.
26. [26] Nathan, D.M., Cleary, P.A., Backlund, J.Y., Genuth, S.M., Lachin, J.M., Orchard, T.J., et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005), 2643–2653.
27. [27] Shantikumar, S., Ajjan, R., Porter, K.E., Scott, D.J., Diabetes and the abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 39 (2010), 200–207.
28. [28] Golledge, J., Karan, M., Moran, C.S., Muller, J., Clancy, P., Dear, A.E., et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J 29 (2008), 665–672.
29. [29] Chait, A., Bornfeldt, K.E., Diabetes and atherosclerosis: is there a role for hyperglycemia?. J Lipid Res 50 (2009), S335–S339 [Suppl.].
30. [30] Miyama, N., Dua, M.M., Yeung, J.J., Schultz, G.M., Asagami, T., Sho, E., et al. Hyperglycemia limits experimental aortic aneurysm progression. J Vasc Surg 52 (2010), 975–983.
31. [31] Saratzis, A., Bown, M., Wild, B., Sayers, R.D., Nightingale, P., Smith, J., et al. C-reactive protein polymorphism rs3091244 is associated with abdominal aortic aneurysm. J Vasc Surg 60 (2014), 1332–1339.
32. [32] Saratzis, A., Bown, M.J., Wild, B., Nightingale, P., Smith, J., Johnson, C., et al. Association between seven single nucleotide polymorphisms involved in inflammation and proteolysis and abdominal aortic aneurysm. J Vasc Surg 61 (2015), 1120–1128.e1.
33. [33] Bown, M.J., Genomic insights into abdominal aortic aneurysms. Ann R Coll Surg Engl 96 (2014), 405–414.
34. [34] Lusis, A.J., Genetics of atherosclerosis. Trends Genet 28 (2012), 267–275.
35. [35] Congrains, A., Kamide, K., Ohishi, M., Rakugi, H., ANRIL: molecular mechanisms and implications in human health. Int J Mol Sci 14 (2013), 1278–1292.
36. [36] Helgadottir, A., Thorleifsson, G., Magnusson, K.P., Gretarsdottir, S., Steinthorsdottir, V., Manolescu, A., et al. The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm. Nat Genet 40 (2008), 217–224.
37. [37] Bown, M.J., Braund, P.S., Thompson, J., London, N.J., Samani, N.J., Sayers, R.D., Association between the coronary artery disease risk locus on chromosome 9p21.3 and abdominal aortic aneurysm. Circ Cardiovasc Genet 1 (2008), 39–42.
38. [38] Harrison, S.C., Smith, A.J., Jones, G.T., Swerdlow, D.I., Rampuri, R., Bown, M.J., et al. Interleukin-6 receptor pathways in abdominal aortic aneurysm. Eur Heart J 34 (2013), 3707–3716.
39. [39] Consortium, IRM, The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet (London, England) 379 (2012), 1214–1224.
40. [40] Leeper, N.J., Raiesdana, A., Kojima, Y., Kundu, R.K., Cheng, H., Maegdefessel, L., et al. Loss of CDKN2B promotes p53-dependent smooth muscle cell apoptosis and aneurysm formation. Arterioscler Thromb Vasc Biol 33 (2013), e1–e10.
41. [41] Bown, M.J., Jones, G.T., Harrison, S.C., Wright, B.J., Bumpstead, S., Baas, A.F., et al. Abdominal aortic aneurysm is associated with a variant in low-density lipoprotein receptor-related protein 1. Am J Hum Genet 89 (2011), 619–627.
42. [42] Jones, G.T., Bown, M.J., Gretarsdottir, S., Romaine, S.P., Helgadottir, A., Yu, G., et al. A sequence variant associated with sortilin-1 (SORT1) on 1p13.3 is independently associated with abdominal aortic aneurysm. Hum Mol Genet 22 (2013), 2941–2947.
43. [43] Schunkert, H., Konig, I.R., Kathiresan, S., Reilly, M.P., Assimes, T.L., Holm, H., et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet 43 (2011), 333–338.
44. [44] Findeisen, H.M., Kahles, F.K., Bruemmer, D., Epigenetic regulation of vascular smooth muscle cell function in atherosclerosis. Curr Atheroscler Rep, 15, 2013, 319.
45. [45] Lund, G., Zaina, S., Atherosclerosis: an epigenetic balancing act that goes wrong. Curr Atheroscler Rep 13 (2011), 208–214.
46. [46] Zhi, Y.F., Huang, Y.S., Li, Z.H., Zhang, R.M., Wang, S.R., Hypermethylation in promoter area of LDLR gene in atherosclerosis patients. Fen Zi Xi Bao Sheng Wu Xue Bao 40 (2007), 419–427.
47. [47] Zaina, S., Heyn, H., Carmona, F.J., Varol, N., Sayols, S., Condom, E., et al. A DNA Methylation Map of Human Atherosclerosis. Circ Cardiovasc Genet 7 (2014), 692–700.
48. [48] Toghill, B., Saratzis, A., Harrison, S., Verissimo, A., Samani, N., Thompson, J., et al. SARS Abstracts, The role of DNA methylation in the pathology of abdominal aortic aneurysms. Br J Surg 103 (2016), 6–49.
49. [49] Fuggle, N.R., Howe, F.A., Allen, R.L., Sofat, N., New insights into the impact of neuro-inflammation in rheumatoid arthritis. Front Neurosci, 8, 2014, 357.
50. [50] Stenvinkel, P., Karimi, M., Johansson, S., Axelsson, J., Suliman, M., Lindholm, B., et al. Impact of inflammation on epigenetic DNA methylation - a novel risk factor for cardiovascular disease?. J Intern Med 261 (2007), 488–499.
51. [51] Zhang, S., Zhong, B., Chen, M., Yang, L., Yang, G., Li, Y., et al. Epigenetic reprogramming reverses the malignant epigenotype of the MMP/TIMP axis genes in tumor cells. Int J Cancer 134 (2014), 1583–1594.
52. [52] Liyanage, V.R., Jarmasz, J.S., Murugeshan, N., Del Bigio, M.R., Rastegar, M., Davie, J.R., DNA modifications: function and applications in normal and disease States. Biology (Basel) 3 (2014), 670–723.
53. [53] Kim, M., Long, T.I., Arakawa, K., Wang, R., Yu, M.C., Laird, P.W., DNA methylation as a biomarker for cardiovascular disease risk. PLoS One, 5, 2010, e9692.
54. [54] Ryer, E.J., Ronning, K.E., Erdman, R., Schworer, C.M., Elmore, J.R., Peeler, T.C., et al. The potential role of DNA methylation in abdominal aortic aneurysms. Int J Mol Sci 16 (2015), 11259–11275.
55. [55] Cahill, L.E., Bertoia, M.L., Aroner, S.A., Mukamal, K.J., Jensen, M.K., New and emerging biomarkers in cardiovascular disease. Curr Diab Rep, 15, 2015, 88.
56. [56] van Holten, T.C., Waanders, L.F., de Groot, P.G., Vissers, J., Hoefer, I.E., Pasterkamp, G., et al. Circulating biomarkers for predicting cardiovascular disease risk; a systematic review and comprehensive overview of meta-analyses. PLoS One, 8, 2013, e62080.
57. [57] Stoner, L., Lucero, A.A., Palmer, B.R., Jones, L.M., Young, J.M., Faulkner, J., Inflammatory biomarkers for predicting cardiovascular disease. Clin Biochem 46 (2013), 1353–1371.
58. [58] Folsom, A.R., Yao, L., Alonso, A., Lutsey, P.L., Missov, E., Lederle, F.A., et al. Circulating Biomarkers and Abdominal Aortic Aneurysm Incidence: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 132 (2015), 578–585.
59. [59] Paffen, E., DeMaat, M.P., C-reactive protein in atherosclerosis: A causal factor?. Cardiovasc Res 71 (2006), 30–39.
60. [60] Powell, J.T., Muller, B.R., Greenhalgh, R.M., Acute phase proteins in patients with abdominal aortic aneurysms. J Cardiovasc Surg 28 (1987), 528–530.
61. [61] Mandaviya, P.R., Stolk, L., Heil, S.G., Homocysteine and DNA methylation: a review of animal and human literature. Mol Genet Metab 113 (2014), 243–252.
62. [62] Antoniades, C., Antonopoulos, A.S., Tousoulis, D., Marinou, K., Stefanadis, C., Homocysteine and coronary atherosclerosis: from folate fortification to the recent clinical trials. Eur Heart J 30 (2009), 6–15.
63. [63] Biselli, P.M., Sanches de Alvarenga, M.P., Abbud-Filho, M., Ferreira-Baptista, M.A., Galbiatti, A.L., Goto, M.T., et al. Effect of folate, vitamin B6, and vitamin B12 intake and MTHFR C677T polymorphism on homocysteine concentrations of renal transplant recipients. Transplant Proc 39 (2007), 3163–3165.
64. [64] Saratzis, A., Bown, M.J., Wild, B., Nightingale, P., Smith, J., Johnson, C., et al. Association between seven single nucleotide polymorphisms involved in inflammation and proteolysis and abdominal aortic aneurysm. J Vasc Surg, 2014.
65. [65] Cao, H., Hu, X., Zhang, Q., Li, J., Wang, J., Shao, Y., et al. Homocysteine level and risk of abdominal aortic aneurysm: a meta-analysis. PLoS One, 9, 2014, e85831.
66. [66] Peeters, A.C., van Landeghem, B.A., Graafsma, S.J., Kranendonk, S.E., Hermus, A.R., Blom, H.J., et al. Low vitamin B6, and not plasma homocysteine concentration, as risk factor for abdominal aortic aneurysm: a retrospective case-control study. J Vasc Surg 45 (2007), 701–705.
67. [67] Liu, Z., Luo, H., Zhang, L., Huang, Y., Liu, B., Ma, K., et al. Hyperhomocysteinemia exaggerates adventitial inflammation and angiotensin II-induced abdominal aortic aneurysm in mice. Circ Res 111 (2012), 1261–1273.
68. [68] Lindqvist, M., Hellstrom, A., Henriksson, A.E., Abdominal aortic aneurysm and the association with serum levels of Homocysteine, vitamins B6, B12 and Folate. Am J Cardiovasc Dis 2 (2012), 318–322.
69. [69] Budoff, M.J., Yang, T.P., Shavelle, R.M., Lamont, D.H., Brundage, B.H., Ethnic differences in coronary atherosclerosis. J Am Coll Cardiol 39 (2002), 408–412.
70. [70] Kuivaniemi, H., Ryer, E.J., Elmore, J.R., Hinterseher, I., Smelser, D.T., Tromp, G., Update on abdominal aortic aneurysm research: from clinical to genetic studies. Scientifica (Cairo), 2014, 2014, 564734.
71. [71] Kent, K.C., Zwolak, R.M., Egorova, N.N., Riles, T.S., Manganaro, A., Moskowitz, A.J., et al. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg 52 (2010), 539–548.
72. [72] Blanchard, J.F., Armenian, H.K., Friesen, P.P., Risk factors for abdominal aortic aneurysm: results of a case-control study. Am J Epidemiol 151 (2000), 575–583.
73. [73] Zeina, A.R., Barmeir, E., Zaid, G., Odeh, M., Coronary artery disease among hypertensive patients undergoing coronary computed tomography angiography. J Cardiovasc Med (Hagerstown) 10 (2009), 252–256.
74. [74] Bartnik, M., Ryden, L., Ferrari, R., Malmberg, K., Pyorala, K., Simoons, M., et al. The prevalence of abnormal glucose regulation in patients with coronary artery disease across Europe. The Euro Heart Survey on diabetes and the heart. Eur Heart J 25 (2004), 1880–1890.